Riskpilot← Back to searchSign inGet full accessDR ATLE KLOVNING AS
ASActiveOrg 989252097Frederik Stangs Gate 31C, 0264 OsloGeneral medical practice activities · NACE 8621Est. 20062 employees
Revenue 2024
NOK 2,2M
-4% vs 2023
EBITDA margin
-23.5%
-388% vs 2023
Equity ratio
-85.3%
Financial strength
Net profit 2024
NOK -515K
-431% vs 2023
| Revenue | NOK 2,2M | -4% |
| EBITDA | NOK -513K | -388% |
| Net profit | NOK -515K | -431% |
| Total assets | NOK 1,6M | -27% |
| Equity | NOK -1,4M | -60% |
| Employees | 2 | — |
Legal name
DR ATLE KLOVNING AS
Org number
989252097
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
4. januar 2006
Share capital
NOK 100 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Drive med allmenn legetjenester, samt hva som står i forbindelse hermed.
Address
Frederik Stangs Gate 31C, 0264 Oslo
Phone
+4755513300
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 671 | 2 864 | 2 380 | 2 268 | 2 185 |
| Staff expenses | −2 671 | −1 467 | −2 101 | −686 | −1 017 |
| EBITDA | 122 | −112 | −879 | 178 | −513 |
| Depreciation & amort. | −13 | −13 | −13 | −12 | −0 |
| EBIT | 109 | −126 | −892 | 166 | −513 |
| Net financials | −76 | −61 | −23 | −11 | −2 |
| Profit before tax | 33 | −187 | −915 | 156 | −515 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 33 | −187 | −915 | 156 | −515 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 391 | 1 217 | 2 446 | 2 191 | 1 604 |
| Equity | 94 | −93 | −1 008 | −852 | −1 367 |
| Long-term debt | 0 | 0 | 900 | 0 | 0 |
| Short-term debt | 1 297 | 1 310 | 2 554 | 3 043 | 2 971 |
| Total debt | 1 297 | 1 310 | 3 454 | 3 043 | 2 971 |
EBITDA margin
-23.5%
This company
15.8%
Market median
-249% vs market
20202024
Equity ratio
-85.3%
This company
38.2%
Market median
-323% vs market
20202024
Return on equity
-51520700.0%
This company
18.4%
Market median
-280003904% vs market
20202024
Net profit margin
-23.6%
This company
8.1%
Market median
-391% vs market
20202024
Asset turnover
1.36×
This company
1.12×
Market median
+21% vs market
20202024
Debt / equity
2.17×
This company
0.62×
Market median
-250% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
EL Deputy Member | Deputy Member | 2006 |
AM Deputy Member | Deputy Member | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2006 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Dr Atle Klovning Investments As
DR ATLE KLOVNING AS Board members of DR ATLE KLOVNING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Egil Lundal | Deputy Member | 0 companies |
| Ann-Kristin Marie Antonie Fjeldstad | Deputy Member | 0 companies |
| Atle Klovning | Chairman | 0 companies |